Your browser doesn't support javascript.
loading
A very-low-calorie ketogenic diet normalises obesity-related enhanced levels of erythropoietin compared with a low-calorie diet or bariatric surgery.
Fernandez-Pombo, A; Lorenzo, P M; Carreira, M C; Gomez-Arbelaez, D; Castro, A I; Primo, D; Rodriguez, J; Sajoux, I; Baltar, J; de Luis, D; Bellido, D; Crujeiras, A B; Casanueva, F F.
Afiliación
  • Fernandez-Pombo A; Epigenomics in Endocrinology and Nutrition Group, Epigenomics Unit, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (CHUS/SERGAS), Travesía da Choupana Street s/n, 15706, Santiago de Compostela, La Coruna, Spain.
  • Lorenzo PM; Endocrinology and Nutrition Division, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS/SERGAS), Santiago de Compostela, Spain.
  • Carreira MC; Epigenomics in Endocrinology and Nutrition Group, Epigenomics Unit, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (CHUS/SERGAS), Travesía da Choupana Street s/n, 15706, Santiago de Compostela, La Coruna, Spain.
  • Gomez-Arbelaez D; CIBER Fisiopatologia de La Obesidad y Nutricion (CIBERobn), Madrid, Spain.
  • Castro AI; CIBER Fisiopatologia de La Obesidad y Nutricion (CIBERobn), Madrid, Spain.
  • Primo D; Molecular Endocrinology Group, Instituto de Investigacion Sanitaria de Santiago de Com-Postela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) and Santiago de Compostela University (USC), Santiago de Compostela, Spain.
  • Rodriguez J; Faculty of Health Sciences, University of Santander (UDES), Bucaramanga, Colombia.
  • Sajoux I; CIBER Fisiopatologia de La Obesidad y Nutricion (CIBERobn), Madrid, Spain.
  • Baltar J; Molecular Endocrinology Group, Instituto de Investigacion Sanitaria de Santiago de Com-Postela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) and Santiago de Compostela University (USC), Santiago de Compostela, Spain.
  • de Luis D; Center of Investigation of Endocrinology and Nutrition, Medicine School and Department of Endocrinology and Investigation, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain.
  • Bellido D; Clinical Biochemistry Laboratory, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS/SERGAS), Santiago de Compostela, Spain.
  • Crujeiras AB; Epigenomics in Endocrinology and Nutrition Group, Epigenomics Unit, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (CHUS/SERGAS), Travesía da Choupana Street s/n, 15706, Santiago de Compostela, La Coruna, Spain.
  • Casanueva FF; Medical Department Pronokal Group, Barcelona, Spain.
J Endocrinol Invest ; 2024 May 02.
Article en En | MEDLINE | ID: mdl-38696124
ABSTRACT

PURPOSE:

Nutritional ketosis synergistically with body-weight loss induced by a very-low-calorie ketogenic diet (VLCKD) has proven to be effective in improving obesity-related pathophysiology. Recently, growing attention has been focused on the relation between erythropoietin (EPO) and obesity. Thus, this study aims to investigate whether nutritional ketosis and weight loss induced by a VLCKD modify the circulating levels of EPO in patients with obesity in comparison with the effect of low-calorie diet (LCD) or bariatric surgery (BS).

METHODS:

EPO levels, iron status and body composition parameters were evaluated in 72 patients with overweight or obesity and 27 normal-weight subjects at baseline and after the three different weight-reduction therapies (VLCKD, LCD and BS) in 69 patients with excess body weight. ß-hydroxybutyrate levels were also measured in the VLCKD group. The follow-up was established at 2-3 months and 4-6 months.

RESULTS:

It was found that EPO levels were higher in morbid obesity and correlated with higher basal weight, fat mass (FM) and fat-free mass (FFM) in the overall sample. High baseline EPO levels were also correlated with higher impact on the course of weight loss and changes in FM and FFM induced by the three weight-loss interventions. Furthermore, the VLCKD induced a decrease in EPO levels coinciding with maximum ketosis, which was maintained over time, while statistically significant changes were not observed after LCD and BS.

CONCLUSION:

The obesity-related increased EPO levels are restored after VLCKD intervention at the time of maximum ketosis, suggesting a potential role of the nutritional ketosis induced by the VLCKD. Baseline EPO levels could be a biomarker of response to a weight-loss therapy.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: J Endocrinol Invest Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: J Endocrinol Invest Año: 2024 Tipo del documento: Article País de afiliación: España